US4789550A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Microcapsule composition suitable for cardiovascular injection
Assignee: Sanofi Pasteur Ltd
•
Filing: 1984-07-16
•
Granted: 1988-12-06
•
Expires: 2004-07-16
Abstract
Abstract Perfectly spherical, smooth and uniform microcapsules, which may contain living cells, are produced having a diameter less than 700 μm, e.g. 150 to about 500 microns, by employing an electrostatic droplet generator. A droplet is suspended from a pointed source, such as a needle, and is charged with high static voltage. A collecting vessel or ring device is charged with opposing polarity and attracts the droplet When a voltage potential threshold is passed, the droplet moves from the source to the collecting vessel. The voltage pulse height, pulse frequency and length, and extrusion rate of the droplet are adjustable so that predetermined sizes of droplets may be repeatedly generated and collected.
Inventors
- 👤 Martin Hommel
- 👤 Anthony Mein-Fang Sun
- 👤 Mattheus F. A. Goosen
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 12:19
CPC Classifications
A; A61; A61L; A61L27/00; A61L27/14; A61L27/20; A61F; A61F2/00; A61F2/02; A61F2/022; A61K; A61K35/00; A61K35/12; A61K35/37; A61K35/39; A61K9/00; A61K9/14; A61K9/16; A61K9/1605; A61K9/1629; A61K9/1652; A61K9/48; A61K9/50; A61K9/5005; A61K9/5021; A61K9/5026; A61K9/5031; A61K9/5073; A61L27/36; A61L27/38; C; C12; C12N; C12N11/00; C12N11/02; C12N11/04; G; G01; G01N; G01N15/00; G01N15/10; G01N15/14; G01N15/149
Claims Analysis
Total Claims: 20
Claim 1
Independent Claim
109 words
A composition of spherical, smooth and uniform microcapsules suitable for cardiovascular injection into an animal body, said microcapsules comprising: a core comprising one or more viable, healthy, physiologically-active tissue cells capable of on going metabolism and an aqueous medium of nutrients sufficient to maintain said tissue cells and allow normal metabolism thereof, and a biocompatible semi-permeable membrane surrounding and enclosing said core, said semi-permeable membrane being permeable to tissue nutrients and metabolic products produced by the tissue but impermeable to immune system proteins, said membrane comprising ionically-interacted biocompatible materials and having a negatively-charged outer surface, said microcapsules having a diameter consisting essentially of about 150 to about 500 microns.
Claim 2
Dependent Claim
109 words
A composition of spherical, smooth and uniform microcapsules suitable for cardiovascular injection into an animal body, said microcapsules comprising: a core comprising one or more viable, healthy, physiologically-active tissue cells capable of on going metabolism and an aqueous medium of nutrients sufficient to maintain said tissue cells and allow normal metabolism thereof, and a biocompatible semi-permeable membrane surrounding and enclosing said core, said semi-permeable membrane being permeable to tissue nutrients and metabolic products produced by the tissue but impermeable to immune system proteins, said membrane comprising ionically-interacted biocompatible materials and having a negatively-charged outer surface, said microcapsules having a diameter consisting essentially of about 150 to about 500 microns.
Claim 3
Dependent Claim
28 words
The microcapsule composition of claim 1 wherein said tissue cells are islets of Langerhans, whereby said cardiovascular injection permits control of blood sugar levels in the animal body.
Claim 4
Dependent Claim
19 words
The microcapsule composition of claim 1 wherein said membrane has a thickness of about 4 to about 6 microns.
Claim 5
Dependent Claim
17 words
The microcapsule composition of claim 2 wherein said islets are entrapped within a reliquifiable reversible gel material.
Claim 6
Dependent Claim
14 words
The microcapsule composition of claim 4 wherein said reversible gel material is calcium alginate.
Claim 7
Dependent Claim
15 words
The microcapsule composition of claim 2 wherein said islets are entrapped within reliquified gel material.
Claim 8
Dependent Claim
15 words
The microcapsule composition of claim 6 wherein said reliquified gel material is aqueous sodium alginate.
Claim 9
Dependent Claim
41 words
The microcapsule composition of claim 1 wherein said semi-permeable membrane is formed about each of the microcapsules by ionic reaction between free acid groups in the surface layer of the gelled reversible gel material and a biocompatible polymer containing acid-reactive groups.
Claim 10
Dependent Claim
14 words
The microcapsule composition of claim 8 wherein said biocompatible polymer is a polyamino acid.
Claim 11
Dependent Claim
23 words
The microcapsule composition of claim 9 wherein the polyamino acid is a polylysine having a molecular weight of about 10,000 to about 30,000.
Claim 12
Dependent Claim
40 words
The microcapsule composition of claim 9 wherein said negatively-charged surface is provided by reacting the biocompatible polymer, after reaction with the gelled reversible gel material, with a non-toxic biocompatible water-soluble polymeric material capable of ionic reaction with free amino groups.
Claim 13
Dependent Claim
14 words
The microcapsule composition of claim 11 wherein said polymeric material is a polysaccharide gum.
Claim 14
Dependent Claim
13 words
The microcapsule composition of claim 12 wherein said polysaccharide gum is sodium alginate.
Claim 15
Dependent Claim
19 words
The microcapsule composition of claim 10 wherein said membrane has a thickness of about 4 to about 6 microns.
Claim 16
Independent Claim
119 words
A method of controlling blood sugar levels in diabetic animals, which comprises: cardiovascularly injecting an effective amount of biocompatible, spherical and smooth microcapsules each having a diameter consisting essentially of from about 150 to about 500 microns, said microcapsules each having (1) a core comprising one or more viable, healthy, physiologically-active islets of Langerhans capable of on-going metabolism to produce insulin and a medium sufficient to maintain said islets of Langerhans and allow normal metabolism thereof and (2) a biocompatible semi-permeable membrane surrounding and enclosing said core, said semi-permeable membrane being permeable to nutrients for the islets and insulin produced thereby but impermeable to immune system proteins, said membrane comprising ionically-interacted biocompatible materials and having a negatively-charged outer surface.
Claim 17
Independent Claim
119 words
A method of controlling blood sugar levels in diabetic animals, which comprises: cardiovascularly injecting an effective amount of biocompatible, spherical and smooth microcapsules each having a diameter consisting essentially of from about 150 to about 500 microns, said microcapsules each having (1) a core comprising one or more viable, healthy, physiologically-active islets of Langerhans capable of on-going metabolism to produce insulin and a medium sufficient to maintain said islets of Langerhans and allow normal metabolism thereof and (2) a biocompatible semi-permeable membrane surrounding and enclosing said core, said semi-permeable membrane being permeable to nutrients for the islets and insulin produced thereby but impermeable to immune system proteins, said membrane comprising ionically-interacted biocompatible materials and having a negatively-charged outer surface.
Claim 18
Dependent Claim
19 words
The method of claim 15 wherein said semi-permeable membrane has a thickness of about 4 to about 6 μm.
Claim 19
Dependent Claim
23 words
The method of claim 15 wherein said medium is a reversible calcium alginate gel material in which at least one islet is suspended.
Claim 20
Dependent Claim
28 words
The method of claim 15 wherein said medium is an aqueous medium alginate solution containing nutrients for said islets and in which at least one islet is suspended.
References Cited (Backward Citations)
US4391909A
Cited
US4409331A
Cited
US4407957A
Cited
US4543332A
Cited
US4673566A
Cited
US4689293A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-12-06 | 1992-06-06 | 1992-12-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-12-06 | 1996-06-06 | 1996-12-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-12-06 | 2000-06-06 | 2000-12-06 | $7700.00 | Window Closed / Lapsed |